OCTAPHARMA USA, INC.
PARAMUS, NJ

OCTAPHARMA USA, INC., incorporated in Florida with a filing number F05000001037 and founded on February 17, 2005, is a company specializing in the development and distribution of life-enhancing and life-saving products for patients suffering from blood clotting disorders, immune deficiencies, and other illnesses. The headquarters are located at 117 West Century Road, Paramus, NJ, with its foundational home state being Virginia. OCTAPHARMA emphasizes close collaboration with patients and healthcare professionals to enhance patient understanding and experiences. Its commitment to safety is reflected through the implementation of solvent-detergent (S/D) treatment processes for viral inactivation, which have maintained no known viral transmissions in over three decades. The company's Expanded Access Program outlines procedures for providing investigational drug access under the 21st Century Cures Act to patients with serious conditions lacking available treatments. OCTAPHARMA adheres to rigorous standards from plasma collection through to manufacturing, ensuring patient safety at every stage of product development. With a legacy dating back to the 1980s as pioneers in virally inactivated Factor VIII production for hemophilia treatment, OCTAPHARMA's mission involves utilizing advanced technologies and human recombinant protein R&D. Its corporate culture is intensely patient-oriented, focusing on market expansion, successful entry into the recombinant business sector, increased plasma availability, organizational health, and transparent communication. OCTAPHARMA remains a leader in the field of therapeutic proteins, guided by strategic principles aimed at expanding its global reach and enhancing organic growth. Its directorate includes notable figures such as Flemming Nielsen (Chair of the Board) and Louis Dicriscio (Treasurer), contributing to its sustained leadership within the healthcare industry.